Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 945

1.

Association between timing of hot water bathing before bedtime and night-/sleep-time blood pressure and dipping in the elderly: a longitudinal analysis for repeated measurements in home settings.

Tai Y, Saeki K, Yamagami Y, Yoshimoto K, Kurumatani N, Nishio K, Obayashi K.

Chronobiol Int. 2019 Oct 15:1-9. doi: 10.1080/07420528.2019.1675685. [Epub ahead of print]

PMID:
31610699
2.

Functional regulation of von Willebrand factor ameliorates acute ischemia-reperfusion kidney injury in mice.

Ono S, Matsui H, Noda M, Kasuda S, Yada N, Yoshimoto K, Akiyama M, Miyata T, Sugimoto M, Nishio K.

Sci Rep. 2019 Oct 8;9(1):14453. doi: 10.1038/s41598-019-51013-2.

3.

Vitrification and nanocrystallization of pure liquid Ni studied using molecular-dynamics simulation.

Louzguine-Luzgin DV, Miyama M, Nishio K, Tsarkov AA, Greer AL.

J Chem Phys. 2019 Sep 28;151(12):124502. doi: 10.1063/1.5119307.

PMID:
31575179
4.

Aberrant HER3 ligand heregulin-expressing head and neck squamous cell carcinoma is resistant to anti-EGFR antibody cetuximab, but not second-generation EGFR-TKI.

Yonesaka K, Tanaka K, Kitano M, Kawakami H, Hayashi H, Takeda M, Sakai K, Nishio K, Doi K, Nakagawa K.

Oncogenesis. 2019 Sep 30;8(10):54. doi: 10.1038/s41389-019-0164-9.

5.

[Current Status and Future Direction of Cancer Genomic Medicine].

Nishio K, Sakai K.

Gan To Kagaku Ryoho. 2019 Sep;46(9):1357-1360. Japanese.

PMID:
31530770
6.

Clinical and immune profiling for cancer of unknown primary site.

Haratani K, Hayashi H, Takahama T, Nakamura Y, Tomida S, Yoshida T, Chiba Y, Sawada T, Sakai K, Fujita Y, Togashi Y, Tanizaki J, Kawakami H, Ito A, Nishio K, Nakagawa K.

J Immunother Cancer. 2019 Sep 13;7(1):251. doi: 10.1186/s40425-019-0720-z.

7.

Longitudinal monitoring of somatic genetic alterations in circulating cell-free DNA during treatment with epidermal growth factor receptor-tyrosine kinase inhibitors.

Iwama E, Sakai K, Hidaka N, Inoue K, Fujii A, Nakagaki N, Ota K, Toyozawa R, Azuma K, Nakatomi K, Harada T, Hisasue J, Sakata S, Shimose T, Kishimoto J, Nakanishi Y, Nishio K, Okamoto I.

Cancer. 2019 Sep 10. doi: 10.1002/cncr.32481. [Epub ahead of print]

PMID:
31503343
8.

Targeting castration-resistant prostate cancer with androgen receptor antisense oligonucleotide therapy.

De Velasco MA, Kura Y, Sakai K, Hatanaka Y, Davies BR, Campbell H, Klein S, Kim Y, MacLeod AR, Sugimoto K, Yoshikawa K, Nishio K, Uemura H.

JCI Insight. 2019 Sep 5;4(17). pii: 122688. doi: 10.1172/jci.insight.122688.

9.

Difficulty classifications of laparoscopic repeated liver resection in patients with recurrent hepatocellular carcinoma.

Kinoshita M, Kanazawa A, Kodai S, Shimizu S, Murata A, Nishio K, Hamano G, Shinkawa H, Tanaka S, Takemura S, Tsukamoto T, Kubo S.

Asian J Endosc Surg. 2019 Aug 13. doi: 10.1111/ases.12746. [Epub ahead of print]

PMID:
31408275
10.

A comparative study of curated contents by knowledge-based curation system in cancer clinical sequencing.

Sakai K, Takeda M, Shimizu S, Takahama T, Yoshida T, Watanabe S, Iwasa T, Yonesaka K, Suzuki S, Hayashi H, Kawakami H, Nonagase Y, Tanaka K, Tsurutani J, Saigoh K, Ito A, Mitsudomi T, Nakagawa K, Nishio K.

Sci Rep. 2019 Aug 5;9(1):11340. doi: 10.1038/s41598-019-47673-9.

11.

Barcode sequencing identifies resistant mechanisms to epidermal growth factor receptor inhibitors in circulating tumor DNA of lung cancer patients.

Kitazono S, Sakai K, Yanagitani N, Ariyasu R, Yoshizawa T, Dotsu Y, Koyama J, Saiki M, Sonoda T, Nishikawa S, Uchibori K, Horiike A, Nishio K, Nishio M.

Cancer Sci. 2019 Oct;110(10):3350-3357. doi: 10.1111/cas.14153. Epub 2019 Aug 19.

12.

Successful long-term treatment of non-small cell lung cancer positive for RET rearrangement with pemetrexed.

Takeda M, Sakai K, Nishio K, Nakagawa K.

Onco Targets Ther. 2019 Jul 8;12:5355-5358. doi: 10.2147/OTT.S211582. eCollection 2019.

13.

Liquid biopsy-based comprehensive gene mutation profiling for gynecological cancer using CAncer Personalized Profiling by deep Sequencing.

Iwahashi N, Sakai K, Noguchi T, Yahata T, Matsukawa H, Toujima S, Nishio K, Ino K.

Sci Rep. 2019 Jul 18;9(1):10426. doi: 10.1038/s41598-019-47030-w.

14.

A Case of Metastatic Malignant Breast Adenomyoepithelioma With a Codon-61 Mutation of HRAS.

Watanabe S, Otani T, Iwasa T, Takahama T, Takeda M, Sakai K, Nishio K, Ito A, Nakagawa K.

Clin Breast Cancer. 2019 Oct;19(5):e589-e592. doi: 10.1016/j.clbc.2019.05.001. Epub 2019 Jun 20. No abstract available.

PMID:
31301988
15.

Reply to A.-M. Conway et al.

Hayashi H, Nishio K, Nakagawa K.

J Clin Oncol. 2019 Aug 10;37(23):2090. doi: 10.1200/JCO.19.00767. Epub 2019 Jun 18. No abstract available.

PMID:
31211602
16.

New Era for Next-Generation Sequencing in Japan.

Takeda M, Sakai K, Takahama T, Fukuoka K, Nakagawa K, Nishio K.

Cancers (Basel). 2019 May 28;11(6). pii: E742. doi: 10.3390/cancers11060742. Review.

17.

Patients with SMARCA4-deficient thoracic sarcoma and severe skeletal-related events.

Kunimasa K, Nakamura H, Sakai K, Tamiya M, Kimura M, Inoue T, Nishino K, Kuhara H, Nakatsuka SI, Nishio K, Imamura F, Kumagai T.

Lung Cancer. 2019 Jun;132:59-64. doi: 10.1016/j.lungcan.2019.03.029. Epub 2019 Apr 8.

PMID:
31097095
18.

Genetic Profiling of Non-Small Cell Lung Cancer at Development of Resistance to First- or Second-Generation EGFR-TKIs by CAPP-Seq Analysis of Circulating Tumor DNA.

Otsubo K, Sakai K, Takeshita M, Harada D, Azuma K, Ota K, Akamatsu H, Goto K, Horiike A, Kurata T, Nakagaki N, Nosaki K, Iwama E, Nakanishi Y, Nishio K, Okamoto I.

Oncologist. 2019 Aug;24(8):1022-1026. doi: 10.1634/theoncologist.2019-0101. Epub 2019 Apr 25.

PMID:
31023862
19.

Spatiotemporal observations of light propagation in multiple polarization states.

Inoue T, Matsunaka A, Funahashi A, Okuda T, Nishio K, Awatsuji Y.

Opt Lett. 2019 Apr 15;44(8):2069-2072. doi: 10.1364/OL.44.002069.

PMID:
30985813
20.

Performance of Oncomine Fusion Transcript kit for formalin-fixed, paraffin-embedded lung cancer specimens.

Sakai K, Ohira T, Matsubayashi J, Yoneshige A, Ito A, Mitsudomi T, Nagao T, Iwamatsu E, Katayama J, Ikeda N, Nishio K.

Cancer Sci. 2019 Jun;110(6):2044-2049. doi: 10.1111/cas.14016. Epub 2019 May 3.

21.

Entropy-driven docosahedral short-range order in simple liquids and glasses.

Nishio K, Lu AKA, Miyazaki T.

Phys Rev E. 2019 Feb;99(2-1):022121. doi: 10.1103/PhysRevE.99.022121.

PMID:
30934319
22.

Indications for laparoscopic liver resection of mass-forming intrahepatic cholangiocarcinoma.

Kinoshita M, Kanazawa A, Takemura S, Tanaka S, Kodai S, Shinkawa H, Shimizu S, Murata A, Nishio K, Hamano G, Ito T, Tsukamoto T, Kubo S.

Asian J Endosc Surg. 2019 Mar 28. doi: 10.1111/ases.12703. [Epub ahead of print]

PMID:
30924307
23.

Substitutional and interstitial impurity p-type doping of thermoelectric Mg2Si: a theoretical study.

Hirayama N, Iida T, Sakamoto M, Nishio K, Hamada N.

Sci Technol Adv Mater. 2019 Mar 14;20(1):160-172. doi: 10.1080/14686996.2019.1580537. eCollection 2019.

24.

Myelodysplastic/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis (MDS/MPN with RS-T) complicated by hyperleukocytosis and gene analysis in relation to leukocytosis.

Aoyama Y, Sakai K, Kodaka T, Tsunemine H, Nishio K, Itoh T, Inoue D, Takahashi T.

J Clin Exp Hematop. 2019 Mar 27;59(1):29-33. doi: 10.3960/jslrt.18037. Epub 2019 Feb 7.

25.

RASGRP2 Suppresses Apoptosis via Inhibition of ROS Production in Vascular Endothelial Cells.

Sato T, Takino JI, Nagamine K, Nishio K, Hori T.

ScientificWorldJournal. 2019 Jan 1;2019:4639165. doi: 10.1155/2019/4639165. eCollection 2019.

26.

Randomized Phase II Trial Comparing Site-Specific Treatment Based on Gene Expression Profiling With Carboplatin and Paclitaxel for Patients With Cancer of Unknown Primary Site.

Hayashi H, Kurata T, Takiguchi Y, Arai M, Takeda K, Akiyoshi K, Matsumoto K, Onoe T, Mukai H, Matsubara N, Minami H, Toyoda M, Onozawa Y, Ono A, Fujita Y, Sakai K, Koh Y, Takeuchi A, Ohashi Y, Nishio K, Nakagawa K.

J Clin Oncol. 2019 Mar 1;37(7):570-579. doi: 10.1200/JCO.18.00771. Epub 2019 Jan 17.

PMID:
30653423
27.

Impact of cytotoxic chemotherapy on PD-L1 expression in patients with non-small cell lung cancer negative for EGFR mutation and ALK fusion.

Sakai H, Takeda M, Sakai K, Nakamura Y, Ito A, Hayashi H, Tanaka K, Nishio K, Nakagawa K.

Lung Cancer. 2019 Jan;127:59-65. doi: 10.1016/j.lungcan.2018.11.025. Epub 2018 Nov 23.

PMID:
30642552
28.

HOXA10 expression profiling in prostate cancer.

Hatanaka Y, de Velasco MA, Oki T, Shimizu N, Nozawa M, Yoshimura K, Yoshikawa K, Nishio K, Uemura H.

Prostate. 2019 Apr;79(5):554-563. doi: 10.1002/pros.23761. Epub 2019 Jan 6.

PMID:
30614022
29.

Evolution of Reactions of a Fluoride Shuttle Battery at the Surfaces of BiF3 Microclusters Studied by In Situ Raman Microscopy.

Yamanaka T, Okazaki KI, Abe T, Nishio K, Ogumi Z.

ChemSusChem. 2019 Jan 24;12(2):527-534. doi: 10.1002/cssc.201802209. Epub 2019 Jan 2.

PMID:
30450797
30.

aCGH Analysis of Predictive Biomarkers for Response to Bevacizumab plus Oxaliplatin- or Irinotecan-Based Chemotherapy in Patients with Metastatic Colorectal Cancer.

Fujita Y, Taguri M, Yamazaki K, Tsurutani J, Sakai K, Tsushima T, Nagase M, Tamagawa H, Ueda S, Tamura T, Tsuji Y, Murata K, Taira K, Denda T, Moriwaki T, Funai S, Nakajima TE, Muro K, Tsuji A, Yoshida M, Suyama K, Kurimoto T, Sugimoto N, Baba E, Seki N, Sato M, Shimura T, Boku N, Hyodo I, Yamanaka T, Nishio K.

Oncologist. 2019 Mar;24(3):327-337. doi: 10.1634/theoncologist.2018-0119. Epub 2018 Nov 13.

PMID:
30425180
31.

A comprehensive gene mutation analysis of liquid biopsy samples from patients with metastatic colorectal cancer to the ovary: A case report.

Iwahashi N, Sakai K, Noguchi T, Yahata T, Toujima S, Nishio K, Ino K.

Oncol Lett. 2018 Nov;16(5):6431-6436. doi: 10.3892/ol.2018.9467. Epub 2018 Sep 20.

32.

Mutational activation of the epidermal growth factor receptor down-regulates major histocompatibility complex class I expression via the extracellular signal-regulated kinase in non-small cell lung cancer.

Watanabe S, Hayashi H, Haratani K, Shimizu S, Tanizaki J, Sakai K, Kawakami H, Yonesaka K, Tsurutani J, Togashi Y, Nishio K, Ito A, Nakagawa K.

Cancer Sci. 2019 Jan;110(1):52-60. doi: 10.1111/cas.13860. Epub 2018 Nov 27.

33.

Extending recordable time of light-in-flight recording by holography with double reference light pulses.

Sawashima Y, Yamanaka D, Takamoto I, Matsunaka A, Awatsuji Y, Nishio K.

Opt Lett. 2018 Oct 15;43(20):5146-5149. doi: 10.1364/OL.43.005146.

PMID:
30320841
34.

Serpina3n, Dominantly Expressed in Female Osteoblasts, Suppresses the Phenotypes of Differentiated Osteoblasts in Mice.

Ishida M, Kawao N, Okada K, Tatsumi K, Sakai K, Nishio K, Kaji H.

Endocrinology. 2018 Nov 1;159(11):3775-3790. doi: 10.1210/en.2018-00639.

PMID:
30304388
35.

An HER3-targeting antibody-drug conjugate incorporating a DNA topoisomerase I inhibitor U3-1402 conquers EGFR tyrosine kinase inhibitor-resistant NSCLC.

Yonesaka K, Takegawa N, Watanabe S, Haratani K, Kawakami H, Sakai K, Chiba Y, Maeda N, Kagari T, Hirotani K, Nishio K, Nakagawa K.

Oncogene. 2019 Feb;38(9):1398-1409. doi: 10.1038/s41388-018-0517-4. Epub 2018 Oct 9.

PMID:
30302022
36.

Exploration of resistance mechanisms for epidermal growth factor receptor-tyrosine kinase inhibitors based on plasma analysis by digital polymerase chain reaction and next-generation sequencing.

Iwama E, Sakai K, Azuma K, Harada D, Nosaki K, Hotta K, Nishio M, Kurata T, Fukuhara T, Akamatsu H, Goto K, Shimose T, Kishimoto J, Nakanishi Y, Nishio K, Okamoto I.

Cancer Sci. 2018 Dec;109(12):3921-3933. doi: 10.1111/cas.13820. Epub 2018 Nov 13.

37.

Structure of glyoxysomal malate dehydrogenase (MDH3) from Saccharomyces cerevisiae.

Moriyama S, Nishio K, Mizushima T.

Acta Crystallogr F Struct Biol Commun. 2018 Oct 1;74(Pt 10):617-624. doi: 10.1107/S2053230X18011895. Epub 2018 Sep 19.

PMID:
30279312
38.

Acid-electrolyzed functional water induces extracellular matrix metalloproteinase inducer, a possible novel alarmin, secretion from oral squamous cell carcinoma cell lines.

Kusunoki M, Sata E, Nishio K, Tanaka T, Nishida T, Sugano N, Sato S, Asano M.

Int J Med Sci. 2018 Sep 7;15(12):1365-1372. doi: 10.7150/ijms.26186. eCollection 2018.

39.

Low-Temperature Spark Plasma Sintering of ZrW2-xMoxO₈ Exhibiting Controllable Negative Thermal Expansion.

Wei H, Hasegawa M, Mizutani S, Aimi A, Fujimoto K, Nishio K.

Materials (Basel). 2018 Sep 1;11(9). pii: E1582. doi: 10.3390/ma11091582.

40.

Clinical practice guidance for next-generation sequencing in cancer diagnosis and treatment (Edition 1.0).

Sunami K, Takahashi H, Tsuchihara K, Takeda M, Suzuki T, Naito Y, Sakai K, Dosaka-Akita H, Ishioka C, Kodera Y, Muto M, Wakai T, Yamazaki K, Yasui W, Bando H, Fujimoto Y, Fukuoka S, Harano K, Kawazoe A, Kimura G, Koganemaru S, Kogawa T, Kotani D, Kuboki Y, Matsumoto H, Matsumoto S, Mishima S, Nakamura Y, Sawada K, Shingaki S, Shitara K, Umemoto K, Umemura S, Yasuda K, Yoshino T, Yamamoto N, Nishio K; Japanese Society of Medical Oncology; Japan Society of Clinical Oncology; Japanese Cancer Association.

Cancer Sci. 2018 Sep;109(9):2980-2985. doi: 10.1111/cas.13730.

41.

Simultaneous detection of lung fusions using a multiplex RT-PCR next generation sequencing-based approach: a multi-institutional research study.

Vaughn CP, Costa JL, Feilotter HE, Petraroli R, Bagai V, Rachiglio AM, Marino FZ, Tops B, Kurth HM, Sakai K, Mafficini A, Bastien RRL, Reiman A, Le Corre D, Boag A, Crocker S, Bihl M, Hirschmann A, Scarpa A, Machado JC, Blons H, Sheils O, Bramlett K, Ligtenberg MJL, Cree IA, Normanno N, Nishio K, Laurent-Puig P.

BMC Cancer. 2018 Aug 16;18(1):828. doi: 10.1186/s12885-018-4736-4.

42.

Heterogeneity of EGFR-mutant clones and PD-L1 highly expressing clones affects treatment efficacy of EGFR-TKI and PD-1 inhibitor.

Kunimasa K, Nakamura H, Sakai K, Kimura M, Inoue T, Tamiya M, Nishino K, Kumagai T, Nakatsuka S, Endo H, Inoue M, Nishio K, Imamura F.

Ann Oncol. 2018 Oct 1;29(10):2145-2147. doi: 10.1093/annonc/mdy312. No abstract available.

PMID:
30099497
43.

Eicosapentaenoic Acid and Prevalence of Cardiovascular Disease in Hemodialysis Patients.

Honda T, Kishi S, Furukawa E, Ambe H, Kurata Y, Ichikawa M, Aoe M, Ohara K, Furuse S, Saito K, Nishio K, Masaki K, Kano T, Mise N.

Ther Apher Dial. 2018 Oct;22(5):514-518. doi: 10.1111/1744-9987.12677. Epub 2018 Jul 10.

PMID:
29987872
44.

A case of ALK-rearranged non-small cell lung cancer that responded to ceritinib after development of resistance to alectinib.

Makuuchi Y, Hayashi H, Haratani K, Tanizaki J, Tanaka K, Takeda M, Sakai K, Shimizu S, Ito A, Nishio K, Nakagawa K.

Oncotarget. 2018 May 1;9(33):23315-23319. doi: 10.18632/oncotarget.25143. eCollection 2018 May 1.

45.

Clinical characteristics of non-small cell lung cancer harboring mutations in exon 20 of EGFR or HER2.

Takeda M, Sakai K, Hayashi H, Tanaka K, Tanizaki J, Takahama T, Haratani K, Nishio K, Nakagawa K.

Oncotarget. 2018 Apr 20;9(30):21132-21140. doi: 10.18632/oncotarget.24958. eCollection 2018 Apr 20.

46.

Effects of Antifreeze Protein Supplementation on the Development of Porcine Morulae Stored at Hypothermic Temperatures.

Nguyen TV, Tanihara F, Hirata M, Hirano T, Nishio K, Kim Do LT, Nguyen TV, Nii M, Otoi T.

Cryo Letters. 2018 Mar/Apr;39(2):131-136.

PMID:
29734422
47.

HER2 genomic amplification in circulating tumor DNA and estrogen receptor positivity predict primary resistance to trastuzumab emtansine (T-DM1) in patients with HER2-positive metastatic breast cancer.

Sakai H, Tsurutani J, Iwasa T, Komoike Y, Sakai K, Nishio K, Nakagawa K.

Breast Cancer. 2018 Sep;25(5):605-613. doi: 10.1007/s12282-018-0861-9. Epub 2018 Apr 26.

48.

A randomized phase II trial of trastuzumab plus capecitabine versus lapatinib plus capecitabine in patients with HER2-positive metastatic breast cancer previously treated with trastuzumab and taxanes: WJOG6110B/ELTOP.

Takano T, Tsurutani J, Takahashi M, Yamanaka T, Sakai K, Ito Y, Fukuoka J, Kimura H, Kawabata H, Tamura K, Matsumoto K, Aogi K, Sato K, Nishio K, Nakagawa K, Saeki T.

Breast. 2018 Aug;40:67-75. doi: 10.1016/j.breast.2018.04.010. Epub 2018 Apr 23.

49.

Thioether Macrocyclic Peptides Selected against TET1 Compact Catalytic Domain Inhibit TET1 Catalytic Activity.

Nishio K, Belle R, Katoh T, Kawamura A, Sengoku T, Hanada K, Ohsawa N, Shirouzu M, Yokoyama S, Suga H.

Chembiochem. 2018 May 4;19(9):979-985. doi: 10.1002/cbic.201800047. Epub 2018 Apr 17.

PMID:
29665240
50.

Genital mucosal melanoma with somatic SF3B1 R625C mutation.

Oiso N, Sakai K, Yanagihara S, Nishio K, Kawada A.

Eur J Dermatol. 2018 Jun 1;28(3):414-415. doi: 10.1684/ejd.2018.3281. No abstract available.

PMID:
29624176

Supplemental Content

Loading ...
Support Center